Evidence map›Paper›PMID 38233601›Full record

ArticleEuropean biophysics journal : EBJ2024

Real-time tilting and twisting motions of ligand-bound states of α7 nicotinic acetylcholine receptor.

Yue Yang, Tatsuya Arai, Daisuke Sasaki, Masahiro Kuramochi, Hidetoshi Inagaki, Sumiko Ohashi, Hiroshi Sekiguchi, Kazuhiro Mio, Tai Kubo, Yuji C Sasaki

Open access · hybridAbstract read
In one paragraph

Article in European biophysics journal : EBJ, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Yue YangGraduate School of Frontier Sciences, The University of Tokyo, Kashiwa, 277-8561, Japan.
Tatsuya AraiGraduate School of Frontier Sciences, The University of Tokyo, Kashiwa, 277-8561, Japan.
Daisuke SasakiGraduate School of Frontier Sciences, The University of Tokyo, Kashiwa, 277-8561, Japan.
Masahiro KuramochiGraduate School of Frontier Sciences, The University of Tokyo, Kashiwa, 277-8561, Japan.
Hidetoshi InagakiBiomedical Research Insitute, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, 305-8566, Japan.
Sumiko OhashiBiomedical Research Insitute, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, 305-8566, Japan.
Hiroshi SekiguchiCenter for Synchrotron Radiation Research, Japan Synchrotron Radiation Research Institute, 1-1-1, Kouto, Sayo-cho, Sayo-gun, Hyogo, 679-5198, Japan.
Kazuhiro MioAIST-UTokyo Advanced Operando-Measurement Technology Open Innovation Laboratory (OPERANDO-OIL), National Institute of Advanced Industrial Science and Technology (AIST), Kashiwa, 277-8565, Japan.
Tai KuboGraduate School of Frontier Sciences, The University of Tokyo, Kashiwa, 277-8561, Japan.
Yuji C SasakiGraduate School of Frontier Sciences, The University of Tokyo, Kashiwa, 277-8561, Japan. ycsasaki@edu.k.u-tokyo.ac.jp.ORCID http://orcid.org/0000-0003-3403-237X
National Institute of Advanced Industrial Science and Technology · JPJapan Synchrotron Radiation Research Institute · JPThe University of Tokyo · JPIbaraki University · JP

Funding

Core Research for Evolutional Science and Technology JP18071859Core Research for Evolutional Science and Technology JSPS 15H02040Core Research for Evolutional Science and Technology JSPS 20H00324Core Research for Evolutional Science and Technology JSPS 26105001Core Research for Evolutional Science and Technology JSPS 26105005Japan Synchrotron Radiation Research Institute 2021B1393Japan Synchrotron Radiation Research Institute 2022A1337Japan Synchrotron Radiation Research Institute 2022B1466
6 · The paper itself

Abstract

The α7 nicotinic acetylcholine receptor is a member of the nicotinic acetylcholine receptor family and is composed of five α7 subunits arranged symmetrically around a central pore. It is localized in the central nervous system and immune cells and could be a target for treating Alzheimer's disease and schizophrenia. Acetylcholine is a ligand that opens the channel, although prolonged application rapidly decreases the response. Ivermectin was reported as one of the positive allosteric modulators, since the binding of Ivermectin to the channel enhances acetylcholine-evoked α7 currents. One research has suggested that tilting motions of the nicotinic acetylcholine receptor are responsible for channel opening and activation. To verify this hypothesis applies to α7 nicotinic acetylcholine receptor, we utilized a diffracted X-ray tracking method to monitor the stable twisting and tilting motion of nAChR α7 without a ligand, with acetylcholine, with Ivermectin, and with both of them. The results show that the α7 nicotinic acetylcholine receptor twists counterclockwise with the channel transiently opening, transitioning to a desensitized state in the presence of acetylcholine and clockwise without the channel opening in the presence of Ivermectin. We propose that the conformational transition of ACh-bound nAChR α7 may be due to the collective twisting of the five α7 subunits, resulting in the compression and movement, either downward or upward, of one or more subunits, thus manifesting tilting motions. These tilting motions possibly represent the transition from the resting state to channel opening and potentially to the desensitized state.

Indexed as

alpha7 Nicotinic Acetylcholine ReceptorReceptors, NicotinicAcetylcholineAllosteric RegulationIvermectinLigandsAcetylcholinealpha7 Nicotinic Acetylcholine ReceptorIvermectinLigandsReceptors, NicotinicDynamicsIvermectinnAChR α7Rotational motionsX-ray single molecule

Identifiers

PMID38233601
PMCPMC10853312
OpenAlexW4390940806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.